WHO antibacterial products in clinical development for priority pathogens (antibiotics and biologicals) that were in phase I-III of clinical development (as of September 2019) and which had not, at that date, received market authorization for human use anywhere in the world are listed here. Candidate products are reported by type, pathogen category, phase of clinical development, and expected activity against priority pathogens. There is also an assessment of their innovativeness and whether a new chemical entity is involved. The route of administration, antibiotic class and developers are also reported.
Aug 25th, 2023